PMID- 20495536
OWN - NLM
STAT- MEDLINE
DCOM- 20110125
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Linking)
VI  - 23
IP  - 10
DP  - 2010 Oct
TI  - Can MDM2 analytical tests performed on core needle biopsy be relied upon to 
      diagnose well-differentiated liposarcoma?
PG  - 1301-6
LID - 10.1038/modpathol.2010.106 [doi]
AB  - Well-differentiated liposarcoma/atypical lipomatous tumor can be difficult to 
      differentiate from benign lipomatous tumors, especially on limited biopsy 
      material. Adjunctive tests for MDM2 (murine double minute 2) have proven useful 
      in whole-tissue sections; however, their utility has not been determined within 
      the increasingly popular core needle biopsy. Herein, we compare the ability of 
      MDM2 immunohistochemistry and MDM2 fluorescence in situ hybridization (FISH) to 
      discriminate benign lipomatous tumors from well-differentiated liposarcoma on 
      core needle biopsies. Well-differentiated liposarcoma (n=17) and an assortment of 
      benign lipomatous tumors (n=37), which had concurrent or previous core needle 
      biopsies, and resection specimens were subjected to both MDM2 
      immunohistochemistry and MDM2 FISH on both whole-tissue sections and 
      corresponding core needle biopsy sections. Percentage tumor cells positive for 
      MDM2 by immunohistochemistry and an MDM2:CEP12 FISH ratio was calculated in each 
      biopsy and resection specimen pair and the results were compared. MDM2 FISH had a 
      higher sensitivity (100%) and specificity (100%) compared with MDM2 
      immunohistochemistry (65 and 89%) in core needle biopsies, respectively. In 
      addition, MDM2 immunohistochemistry had a false-positive rate of 11%, compared to 
      0% with FISH. The average MDM2:CEP12 ratio was similar in the biopsy material 
      compared with the whole-tissue sections in both well-differentiated liposarcoma 
      and the benign lipomatous tumor group of neoplasms. Detection of MDM2 
      amplification by FISH is a more sensitive and specific adjunctive test than MDM2 
      immunohistochemistry to differentiate well-differentiated liposarcoma from 
      various benign lipomatous tumors, especially on limited tissue samples.
FAU - Weaver, Joshua
AU  - Weaver J
AD  - Department of Anatomic Pathology, Pathology and Laboratory Medicine Institute, 
      Cleveland Clinic, Cleveland, OH 44195, USA.
FAU - Rao, Priya
AU  - Rao P
FAU - Goldblum, John R
AU  - Goldblum JR
FAU - Joyce, Michael J
AU  - Joyce MJ
FAU - Turner, Sondra L
AU  - Turner SL
FAU - Lazar, Alexander J F
AU  - Lazar AJ
FAU - Lopez-Terada, Dolores
AU  - Lopez-Terada D
FAU - Tubbs, Raymond R
AU  - Tubbs RR
FAU - Rubin, Brian P
AU  - Rubin BP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20100521
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
SB  - IM
MH  - Biomarkers, Tumor/*analysis
MH  - *Biopsy, Needle
MH  - Diagnosis, Differential
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lipoma/diagnosis
MH  - Liposarcoma/*diagnosis/metabolism
MH  - Proto-Oncogene Proteins c-mdm2/*biosynthesis
MH  - Sensitivity and Specificity
EDAT- 2010/05/25 06:00
MHDA- 2011/01/28 06:00
CRDT- 2010/05/25 06:00
PHST- 2010/05/25 06:00 [entrez]
PHST- 2010/05/25 06:00 [pubmed]
PHST- 2011/01/28 06:00 [medline]
AID - S0893-3952(22)02636-9 [pii]
AID - 10.1038/modpathol.2010.106 [doi]
PST - ppublish
SO  - Mod Pathol. 2010 Oct;23(10):1301-6. doi: 10.1038/modpathol.2010.106. Epub 2010 
      May 21.